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Abstract
Hearing impairment is common in patients with mucopolysaccharidoses (MPS) in 
the preschool age. Conductive or mixed hearing loss is the most frequent occurrence 
while the involvement of the inner ear or central auditory pathways may occur in more 
severe forms. A retrospective review of 82 children with MPS admitted at the Pediatric 
Department of the University of Milano Bicocca was performed to determine the inci-
dence of otological symptoms. We focused particularly on audiological investigations in 
a subgroup of 47 children diagnosed before 6 years of age (MPS I, n = 11 patients; MPS II, 
n = 10; MPS III, n = 7; MPS IV, n = 14; MPS VI, n = 5). In 37 children, a magnetic resonance 
imaging (MRI) of the brain and cervical spine was also performed in order to correlate 
the audiological findings with the imaging of the middle and inner ear. A total of 40 out 
of 47 children (86%) showed some degree of hearing impairment: sensorineural or mixed 
hearing loss in 23 cases (48.93%) and retrocochlear in 4 (8.51%). MRI ascertained mul-
tiple CNS abnormalities in 13 (35.3%): dilated perivascular spaces in 5 (38.5%); dilated 
ventricular cavities in 5 (38.5%); demyelinated and gliotic areas in 3 (23.0%). Conversely, 
one-fourth of the children’s inner ears showed some morphological anomaly (24.3%).
Keywords: mucopolysaccharidoses, hearing loss, auditory brainstem responses (ABR), 
transient-evoked otoacoustic emissions (TEOAE), MRI
1. Introduction
Mucopolysaccharidoses (MPSs) are a group of rare inherited metabolic disorders resulting 
from deficiencies of enzymes involved in the breakdown of glycosaminoglycans (GAGs). 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
MPS disorders have an overall incidence reported of 1.53 per 100,000 live births ranging 
from 1 in 150,000 to as high as 1 in 10,000 live births [1]. The highest birth prevalence was 
0.84 for MPS II, accounting for 55% of all MPS. MPS I, III, and IV accounted for 15, 16, 
and 10%, respectively. MPS VI and VII were more rare and accounted for 1.7 and 1.3%, 
respectively.
The majority are characterized by an autosomal recessive pattern (except for X-linked MPS II 
type). The deficiency of one of the enzymes participating in the GAGs degradation pathway 
causes progressive storage in the lysosomes, leading to cellular, tissues and organs dysfunc-
tion. The damage is both direct or by activation of secondary and tertiary pathways among 
which a role is played by inflammation.
Nowadays 11 different enzyme deficiencies are known to be involved in MPSs producing 
seven distinct clinical phenotypes. In contrast to a recent past when there was only palliative 
treatment for these diseases, now many specific treatments like hematopoietic stem cell trans-
plantation (HSCT) in selected cases (severe MPS I) and enzyme replacement therapy (ERT) 
for MPS I, II, IV and VI are available.
MPSs can manifest as severe or attenuated clinical picture. The “severe” forms frequently 
appear in the first 2–3 years of life with skeletal abnormalities often accompanied by 
dysmorphic facies, organomegaly, multiple hernias (inguinal, umbilical), abnormally 
frequent and severe upper airways infections, otitis media and chronic rhinitis. In the 
“attenuated” forms of the disease instead, the progression of signs and symptoms is much 
slower [2, 3].
These patients may show the prevalent involvement of a single organ and are often seen by 
one or two specialists for years before reaching the diagnosis [2, 3].
The most frequent signs of presentation are cardiac valve disease, eye disease, hearing loss, 
carpal tunnel syndrome and functional limitation of major joints [4–6].
In both forms, the disease invariably progresses with time. MRI of the brain and cervical spine 
is recommended at the time of diagnosis and at regular intervals thereafter [7].
Surgery to stabilize the spine by posterior fusion can be life-saving. Both central and periph-
eral nervous systems are affected in the MPSs. Prominent perivascular spaces, hydrocepha-
lus, brain atrophy, gliosis and white matter changes are common [8, 9].
The communicating hydrocephalus that occurs in MPSs is usually slowly progressive, with 
mild or absent clinical symptoms. Corneal clouding in MPS I, IV, VI and VII may lead to sig-
nificant visual disability. Glaucoma and cataracts have been reported in MPS I and MPS VI 
and in MPS III and IV respectively [10].
In the ENT field, these patients often present obstructive sleep apnea/hypopnea (OSAHS), noisy 
breathing, upper respiratory tract infections, chronic rhinitis, frequent middle ear infections 
and mixed (conductive + sensorineural) hearing loss. The conductive component is explained 
by Eustachian tube obstruction or insufficiency by macroglossia, pharyngeal and soft palate 
mucosal swelling, hyperplasia of adenoids and tonsils. Occasionally, congenital deformities 
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of the middle ear ossicles are observed. Treatments with continuous positive airways pressure 
(CPAP) during the night sleep, adenotonsillectomy, grommets insertion and hearing aids may 
be needed [11]. The sporadic finding of sensorineural hearing loss is related to the central and 
peripheral nervous systems involvement; in some instances it is retrocochlear in nature [12], 
and it slowly worsens over time [13]. In this study, we reviewed the clinical data of a consecu-
tive series of patients with MPSs, focusing on the early involvement of the auditory pathways.
2. Materials and methods
A retrospective chart review was undertaken to document the otological clinical features and 
the hearing status of a group of 82 children affected by MPS who were consecutively admitted 
at the Department of Pediatrics of the San Gerardo Hospital, University of Milano-Bicocca, 
Monza, Italy, for diagnostic purposes. The young patients were included in the study at the 
end of the diagnostic process, when the disease had been already characterized by its enzy-
matic and genetic substrate. Thus, the diagnosis was definite in all cases. We then selected to 
restrict the investigation to a subgroup of 47 younger children, aged less than 6 years, in order 
to define audiological profiles with an early prognostic value and early treatment.
We classified the 47 children according to the known MPS types (Table 1).
All children underwent an ENT examination during their in-hospital admission, including 
fiberoptic endoscopy of the upper airways and otomicroscopy. The audiological workup 
included:
1. Either behavioral audiometry (children <4 years of age) or pure-tone audiometry (children 
>4 years of age): they were conducted in a soundproof booth, with procedures adequate 
for the child’s age: (a) infants: conditioned oriented responses—COR; (b) toddlers: play 
audiometry; (c) older children: air (AC) and bone conducted (BC) six frequencies pure tone 
threshold determination with conventional procedures
2. Middle ear impedance testing: tympanograms and contralateral stapedial reflexes
3. Auditory brainstem responses (ABR): responses elicited by 0.1 ms alternated polarity clicks 
at intensities decreasing by 10 dB-steps starting from 120 dB p.e.SPL, via ER3A inserts; the 
electrodes setup was A1/A2-Cz-Fpz; the electrodes impedance <5 kOhm; threshold estima-
tion was obtained by visually checking the wave V latencies and by a test/retest procedure 
of the lowest amplitude recognizable of the Vth peak. In younger children the procedure 
was performed during spontaneous sleep; in selected instances, it was obtained during the 
sedation required for the MR imaging.
Criteria for labeling a response as “abnormal” were the following:
• Absence of any of the III main wave peaks
• Increased latency of any peak, compared with the normative data for the corresponding 
age groups at the Audiology Service
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• Increased interpeak latency (IPI) compared with the normative data
• Interaural latency difference greater than 0.20 ms
A test/retest procedure was applied at 120 dB SPL stimulation and at the wave V threshold 
tracing.
A control group of 20 normally hearing children aged 1 year (normative 1), 20 children aged 
18–24 months (normative 2) and 20 aged 3–6 years (normative 3) provided the ABR waves laten-
cies normative data.
Therefore, we selected to restrict the investigation to a subgroup of younger children, aged 
less than 6 years. A full set of audiological data was then gathered for these 47 younger chil-
dren; among them, 37 (80.43%) underwent also an MRI of the brain and ear. It was therefore 
possible to cross-check the outcomes of the hearing test and neuroradiological imaging in this 
subgroup of 37 children. They were 21 males and 16 females with a median age at admission 
of 3.2 years, ranging between 12 months and 6 years. Figure 1 shows the flowchart of the 
study protocol.
In the majority of cases the MRIs of the brain and ear were performed under slight sedation 
(infants, toddlers and uncooperative children). The MRIs were obtained by a basic protocol 
Disease Number of 
observed 
cases
Defective enzyme GAG storage 
material
Estimated  
incidence
MPS-I (Hurler, 
Hurler/Scheie Scheie)
11 α-L-Iduronidase Dermatan sulfate, 
heparan sulfate
1:84,000
MPS-II (Hunter) 10 Iduronate-2-sulfatase Dermatan sulfate, 
heparan sulfate
1:196,000
MPS-IIIa (Sanfilippo 
A)
7 Heparan N-sulfatase Heparan sulfate 1:92,000
MPS-IIIb (Sanfilippo 
B)
N-Acetyl-α-glucosaminidase Heparan sulfate 1:157,000
MPS-IIIc (Sanfilippo 
C)
Acetyl-CoA:α-glucosamide 
N-acetyltransferase
Heparan sulfate 1:714,000
MPS-IIId (Sanfilippo 
D)
0 N-Acetylglucosamine-6-sulfatase Heparan sulfate 1:1,000,000
MPS-IVA (Morquio A) 14 Galactose-6-sulfatase Keratan sulfate, 
chondroitin-6-sulfate
1:131,000
MPS-IVB (Morquio B) Beta-galactoidase Keratan sulfate 1:130,000
MPS-VI 
(Maroteaux-Lamy)
5 Arylsulfatase B Dermatan sulfate 1:120,000
Table 1. Clinical types of mucopolysaccharidosis (MPSs) with their underlying enzyme deficiency, accumulated 
substrate, and relative incidence.
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including axial, coronal and sagittal 3D–Steady-State Free Procession sequence (SSFP), 
T1-weighted Fast Spin-Echo (FSE) sequence, and T2-weighted 3D Fluid Attenuated Inversion 
Recovery (FLAIR) sequence. MRI scans were extended from top of the skull to C7. No intra-
venous injection of contrast medium was applied as a standard procedure. An expert senior 
Neuroradiologist categorized the findings according to the three most prevalent patterns: 
(a) dilated perivascular spaces; (b) dilated ventricular cavities; (c) demyelinated and gliotic areas.
After establishing an audiological diagnosis in terms of presence and type of hearing loss 
(conductive, mixed, sensorineural  cochlear or retrocochlear), degree of loss, laterality, and 
checking the eardrum morphology at otomicroscopy, these data were contrasted with the 
MRI findings.
Children were divided in two groups according to the type of hearing loss: “C” = purely con-
ductive; “S” = sensorineural or mixed that is reported in Figure 2.
Figure 1. Flowchart showing the young patients’ distribution according to the tests performed in the current study.
Figure 2. Mean hearing thresholds levels in the “mixed” (left panel) and in the “sensorineural” hearing loss group (right 
panel). n = 47.
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3. Results
3.1. Audiological workup
Some degree of hearing impairment was present in 61 children (74.4%) of the whole cohort of 
82 young patients (up to 14 years of age). A total of 21 children (25.6%) were normally hearing. 
Approximately the same rate of hearing impairment was found in 36 children of the cohort 
47 under 6 years of age (76.6%) rather than at older ages; it was sensorineural or mixed in almost 
half of the ears (47.44%) and purely conductive in about one-third (27.02%). Hearing loss was 
always symmetrical in the two ears (within 10 dB differences between ears at same frequencies).
Five children presented with normal hearing at admission (mean PTA <20 dB HL bilaterally). 
The average AC threshold in the “C” group was 44 dB HL with an air-bone gap (ABG) of 
21 dB HL; the “S” group showed an AC threshold PTA = 62.5 dB HL with an ABG of 2.3 dB HL. 
In 7 children (18.9%), the tympanograms were normal (type “A”) at the time of the initial 
assessment and contralateral stapedial reflexes showed a normal threshold and morphology; 
in the other 30 (81.0%) they were pathological in both ears (Type “B” n = 14; type “C” n = 16).
Transient evoked otoacoustic emissions (TEOAE) were absent bilaterally in all children 
with a hearing threshold worse than 25 dB HL; normal otoacoustic emission responses were 
obtained in 9 out of 10 normally hearing ears.
Normative latencies for the three main ABR peaks in normally hearing children of different 
ages are reported in Table 2, and compared to those obtained in the MPS cohort stratified in 
the same three age groups. Statistical analysis was performed by means of Wilcoxon signed 
rank test; p < 0.005 was considered statistically significant.
In MPS children, ABRs to click stimuli were morphologically normal with peak latencies 
within normal limits (avg ± 1 SD) in 25 out of 47 subjects (53.2%), whereas 22 tracings showed 
abnormalities (46.8%). A typical waveform with the 3 main peaks was recognizable or only 
wave I was missing in 18 of these 22 cases at a stimulus intensity of 90 dB HL, but the ampli-
tudes were reduced and all the latencies delayed (“cochlear” site of lesion); in 7 children no 
Wave  
latencies
MPS 12  
mo
Norm  
1
p MPS  
18–24 mo
Norm  
2
p MPS  
2–6 ys
Norm  
3
p
Wave I 1.89 ± 0.21 1.62 ± 0.31 0.046 2.01 ± 0.18 1.88 ± 0.26 n.s. 2.18 ± 0.29 1.99 ± 0.48 n.s.
Wave III 4.30 ± 0.12 4.00 ± 0.34 n.s. 4.51 ± 0.25 4.12 ± 0.11 0.0001 4.45 ± 0.22 4.17 ± 0.3 0.0001
Wave V 6.39 ± 0.18 5.92 ± 0.25 0.0001 7.02 ± 0.2 5.96 ± 0.28 0.0001 7.39 ± 0.26 5.98 ± 0.11 0.0001
IPI I–III 2.40 ± 0.22 2.37 ± 0.21 n.s. 2.50 ± 0.31 2.24 ± 0.25 n.s. 2.27 ± 0.22 2.18 ± 0.21 n.s.
IPI I–V 4.33 ± 0.1 4.31 ± 0.16 n.s. 5.01 ± 0.18 4.98 ± 0.16 n.s. 5.21 ± 0.1 4.0 ± 0.26 0.0001
Latency values expressed in ms. Wilcoxon signed rank test, statistical significance at p < 0.005.
Table 2. ABR’s absolute wave latencies (ms) and inter-peak intervals (IPI, ms) in the MPS cohort stratified by age and 
compared to those obtained in the normally hearing age-matched children (control groups Norm 1-2-3).
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identifiable response was obtained: in 3 of them, the hearing threshold was severe enough to 
explain the absence of the response; in 4 cases a retrocochlear involvement was suspected. 
Overall, a retrocochlear involvement was likely in 8.5% of MPS children.
The relationship between the MPS types and the ABR findings is shown in Table 3: all chil-
dren with MPS III demonstrated an altered ABR; the greatest majority of MPS II also proved 
pathological, as well as half of the MPS I. None of the patients affected by MPS IVA and VI 
revealed abnormal ABR tracings.
According to ABR response, the hearing loss was of the “cochlear” type in 83.3, 77.8 and 85.7% 
of MPS I, MPS II and MPS III, respectively. One case of absent wave I plus absent or delayed 
wave III and V were observed in MPS I and III, similarly to two cases of MPS II. In no instance 
an isolated delay of wave V was observed, thus excluding purely “central” site of lesions.
In most MPS children with hearing loss, the hearing threshold derived from the ABRs wave V 
thresholds ranged between 70 and 90 dB SPL (40–60 dB HL) with an average of 85.62 dB SPL.
3.2. Neuroimaging
Among the 37 MRI, 14 (37.84%) were normal, whereas 23 (62.16%) were pathologic. The 
most frequent abnormal neuroradiological findings were represented by dilated perivascular 
spaces (due to extracellular storage of GAGs) in = 12 (32.43%); dilated ventricular cavities 
n = 15 (40.54%); demyelinated and gliotic areas n = 9 (24.32%). The frequent observation of a 
J-shaped sella was considered a non-pathological anatomical variant.
We reviewed all MRI with a particular attention on the middle and inner ear findings, 
although imaging was a standard brain study, not addressing the ear morphology per se. We 
ascertained five cases of globose internal auditory canal (IAC), and one case of cystic cochlear 
MPS type Normal latencies (all 
peaks recognizable)
Abnormal 
ABR
Absent wave I or delayed 
wave I-III-V (cochlear 
hearing loss (IPI within 
normal range)
Absent wave I 
and absent or 
delayed wave III 
and V
Delayed 
wave V only
MPS-I 
(n = 11)
5 (46.5%) 6 (54.5%) 5 1 0
MPS-II 
(n = 10)
1 (10%) 9 (90%) 7 2 0
MPS III 
(n = 7)
0 7 (100%) 6 1 0
MPS IV 
(n = 14)
14 0 0 0 0
MPS VI 
(n = 5)
5 0 0 0 0
Total 25/47 (53.2%) 22/47 (46.8%) 18 (81.8%) 4 (8.5%) 0
Table 3. Distribution of abnormal ABR findings according to MPS type (n = 47).
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apex and dilated vestibule, which is shown in Figure 3. All detected anomalies were bilat-
eral except for the dilated vestibule (right ear, pt. # 14). The middle ear pathological findings 
consisted in 15 cases of sero-mucinous effusion in the mastoid cells and in the tympanic cav-
ity, 9 bilateral and 4 unilateral (always the right side). In no instance an enlarged vestibular 
aqueduct was detected. Similarly, no pathological conditions were identified along the central 
auditory pathways in any young MPS patients.
We further stratified the 37 MR+ patients in 3 subgroups related to age: 5 (13.51%) patients 
were under 1 years old, only 2 children (5.4%) were between 1 and 2 years old and 30 children 
Age # of patients (%) Rate of pathological ABRs Rate of pathological brain MRIs
<1 year 5 2 (40%) 3 (60%)
1–2 years 2 2 (100%) 1 (100%)
2–6 years 30 23 (77.7%) 22 (72.2%)
Total 37 27 (72.9%) 26 (70.2%)
Table 4. Incidence of pathological ABRs and MRIs at different ages in the subgroup of 37 MPS patients who underwent 
both investigations.
Figure 3. Detail of axial T2-weighted MRI scan of the right ear of patient #14, showing cystic cochlear apex (thin arrow) 
and enlarged vestibule (empty arrow).
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(81.08%) were between 2 and 6 years old. By contrasting the rate of pathological ABR and the 
MRI findings according to the age layers we obtained the outcomes illustrated in Table 4. 
Noticeably, the majority of children underwent an ABR after 2 years of age, when, theoreti-
cally, the physiological maturation of the central auditory pathways should be completed.
4. Discussion
The MPSs are a group of monogenic disorders due to lysosomal storage of glycosaminoglycans 
(GAGs), previously called mucopolysaccharides [14]. The deficiency of one of the enzymes 
participating in the GAGs degradation pathway causes progressive storage in the lysosomes 
and cytoplasm, leading to cell swelling and multiple organs dysfunction. The damage is both 
direct or by activation of secondary and tertiary pathways among which a role is played by 
inflammation. [15] All MPSs have an autosomal recessive transmission with the exception of 
MPS type II (Hunter syndrome) which is X-linked [16].
The incidence of MPSs as a group is reported between 1:25,000 and 1:45,000 [17]. At present, 
11 different enzyme deficiencies are involved in MPSs producing 7 distinct clinical pheno-
types [14] (Table 1). Depending on the enzyme deficiency, the catabolism of dermatan sulfate, 
heparin sulfate, keratin sulfate, chondroitin sulfate, or hyaluronan may be impaired, singu-
larly or in combination.
MPSs virtually affect all organs and tissues and show a progressive worsening with time. 
Diagnosis is suspected clinically on the basis of rather constant physical appearance (signs 
can be subtle or overt) such as: coarse facial features; short stature; “claw hand” and/or joint 
stiffness or ligamentous laxity (seen in MPS VI); corneal clouding (from very mild to severe), 
retinopathy, glaucoma; chronic nasal congestion, noisy breathing; abdominal protuberance 
owing to liver and spleen enlargement; spinal deformity (gibbus, scoliosis, kyphosis, lordo-
sis); abnormal gait (e.g., toe walking); hearing deficits and brain involvement with progres-
sive cognitive delay. In MPS III and II, mental retardation at 2–3 years may be the only, or 
most evident, presenting sign. Heart failure and severe valve disease in the first year of life are 
reported as the first presenting symptom in the severe forms [18–20]. In these patients, quality 
of life and life span are generally substantially reduced [21, 22].
The attenuated forms have widely variable clinical presentations with different presenting 
signs at different ages, often one or few organs only clinically manifest the disease [2, 3]. In 
these milder forms the progression of signs and symptoms is much slower than in the severe 
ones. These patients may have a presentation apparently limited to one organ only and are 
often seen by a specialist for years before reaching the diagnosis [2, 3], that is usually accom-
plished by means of biochemical, enzymatic and molecular tests.
Currently, specific treatments such as hematopoietic stem cell transplantation in selected 
cases of severe MPS I and enzyme replacement therapy for MPS I, II, IV and VI are available 
[23]. These treatments are able to improve the clinical course of the disease if started early. 
This brings along the responsibility for the clinician to recognize these diseases at the first 
signs to allow access to treatment before a severe damage has been established.
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Although similar, each type of MPSs has a peculiar phenotypic expression [14]; besides, 
within the same type of MPSs, the phenotypic spectrum is largely variable, as a result of the 
different severity of mutations and overall genetic background of the single individual.
The otorhinolaryngological involvement is represented by otitis media with effusion, pro-
gressive mixed hearing loss, OSAHS, pathology of the Waldeyer lymphatic ring and difficul-
ties during intubation [24].
In the severe forms, which most frequently present in the first 2–3 years of life with skeletal abnor-
malities dysmorphic facies, organomegaly and multiple hernias, children suffer abnormally fre-
quent and severe upper airways infections, chronic rhinitis and otitis media. Hearing loss is a 
frequent feature of the more severe forms of MPS; therefore, it should be identified as early as 
possible in order to help assessing a correct diagnosis and provide an etiological treatment [33].
It occurs frequently in the early childhood, mainly as a consequence of recurrent episodes 
of otitis media. It is often discovered occasionally, during an otorhinolaryngological referral 
requested for the control of the upper airways. OME is the most frequent finding: if the clini-
cal history is silent, it may be overlooked; its incidence in children affected by MPS is higher 
than in the general population [24].
A middle ear effusion can easily mask an underlying sensorineural hearing loss. The inner ear 
involvement has been generally neglected in the literature; the major pathologic alterations 
have been found in the Corti organ, tectorial and Reissner’s membranes, ciliated cells and 
auditory nerve [13]. In the attenuated forms of MPS, hearing loss occurs more frequently at a 
later stage, but it sometimes develops already in first infancy. If correctly recognized, it can 
be effectively rehabilitated with hearing aids, reducing the already existing disability related 
with the multi-organ dysfunction.
In our series, 32% of the young patients were affected by mixed hearing loss, 28% by purely 
conductive, 16% by sensorineural type and 24% were normally hearing. This distribution 
is coherent with other reports [25, 26]. The degree of hearing loss in purely sensorineural 
involvement ranged between 40 and 60 dB (average 55.62 dB HL).
In our MPS children, auditory brainstem responses to click stimuli were morphologically 
normal with peak latencies within normal limits (avg ± 1 SD) in 25 out of 47 subjects (53.2%), 
whereas 22 tracings showed abnormalities (46.8%). At a stimulus intensity of 90 dB HL, the 3 
main peaks of the typical ABR waveform were recognizable, or only wave I was missing, in 18 
of these 22 cases. Reduced amplitudes and delayed latencies with regular interpeak latencies 
indicated a “cochlear” site of lesion; in 7 children no identifiable response was obtained: in 3 
of them the hearing threshold was severe enough to explain the absence of the response; in 4 
cases a retrocochlear involvement was suspected. Overall, a retrocochlear involvement was 
likely in 8.5% of MPS children.
The relationship between the MPS types and the ABR findings is shown in Table 3: all chil-
dren with MPS III demonstrated an altered ABR; the greatest majority of MPS II also proved 
pathological, as well as half of the MPS I. None of the patients affected by MPS IVA and VI 
revealed abnormal ABR tracings. On a speculative basis, this might reflect a more severe com-
promise of the auditory periphery in MPS I-II and III.
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Based on the ABR response, the hearing loss was of the “cochlear” type in 83.3, 77.8 and 85.7% 
of MPS I, MPS II and MPS III, respectively; purely “central” lesions were excluded.
The retrocochlear patterns of auditory evoked potentials observed in four of our patients with 
sensorineural hearing loss highlighted a conduction delay within the central auditory system, 
possibly related to progressive storage of GAGs.
Up to date, the reason for the sensorineural component of the hearing loss has not been 
fully ascertained: some alterations, such as the presence of lysosomal deposit in the outer 
and /or inner hair cells suggest a dysfunction of the cochlear sensorial structures; con-
versely, the findings of PAS+ material occupying the cytoplasm of the spiral and vestibular 
ganglion cells might indicate an altered neural transmission [27, 28]. Furthermore, animal 
studies also showed an alteration in the mechanical properties of the Reissner’s and Basilar 
membranes [12].
The most characteristic modification in the CNS is the dilatation of the perivascular spaces, 
caused by extracellular storage of GAGs; it appears as a variable amount of tiny spot-like 
cystic lesions with CSF-like signal in all sequences. It is probably determined by large GAG 
inclusions between vascular adventitial cells, typically at basal ganglia, subcortical parietal 
and occipital white matter, and in the corpus callosum, with radial orientation along the vas-
cular developmental lines [29]. Widening of liquoral spaces and hydrocephalus, secondary to 
pathologic leptomeningeal thickening with resorption deficit by the Pacchioni’s granulations 
and/or obstruction of the CSF flow, can lead to severe neurologic compromise (requiring a 
shunt) or to neuronal loss and decrease of association fibers and atrophy [30]. The expression 
of white matter dystrophy in mucopolysaccharidoses, probably on a microvascular basis, is 
common also to several other diseases that share the same vulnerable areas, such as the peri-
trigonal white matter. Compared to dilated perivascular spaces, these lesions show brighter 
(hyperintense) signals both in T
2
-weighted and FLAIR images.
In our series of 37 MPS children who underwent MRI, 14 (37.84%) were normal, whereas 23 
(62.16%) showed some abnormalities such as dilated perivascular spaces in 12 (32.43%), dilated 
ventricular cavities in 15 (40.54%), demyelinated and gliotic areas in 9 (24.32%). A globose 
internal auditory canal was observed in five cases of IAC, and a cystic cochlear apex and dilated 
vestibule in 1 child. The middle ear pathological findings consisted in 15 cases of sero-mucinous 
effusion in the mastoid cells and in the tympanic cavity. The limited number of children 
tested under 2 years of age does not allow to draw general conclusions. Instead, within the 
group of 30 children aged 2–6 years, the rate of pathological ABRs (77.7%) and of pathologi-
cal MRI of the brain (72.2%) showed a high degree of correlation. Assuming that the physi-
ological maturation of the central auditory pathways is being completed during this age 
range, the ABR abnormalities would possibly be attributed no longer to a delayed myelin-
ization. Therefore, the “retrocochlear” ABR findings might be a real expression of “central” 
auditory dysfunction, although the MRI abnormalities did not seem to involve directly the 
auditory pathways.
The interpretation of these neuroimaging findings is somehow challenging, because a clear 
relationship with cognitive insufficiency in MPS patients is lacking [30, 31], although mental 
retardation has been reported in the more severe forms of MPS 1 [32–37].
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Similarly, the relationship with hearing loss is not clear. Nevertheless, a prompt recognition 
of the hearing difficulties, which can be among the first manifestations of the disease, might 
help assessing an earlier diagnosis and, therefore, provide a timely treatment.
5. Conclusions
Inner ear and retrocochlear involvement in MPS patients is more frequent than initially sus-
pected. Observation of seromucinous effusion in the middle ear does not exclude the presence 
of a sensorineural hearing loss. An otological and audiological investigation should be war-
ranted to all defined or suspected MPS patients. Inner ear or central auditory lesions detected 
by the audiological tests should be further investigated by specific MR imaging processing 
algorithms.
Early identification of hearing loss not only enables proper acoustic rehabilitation, but also 
supports the diagnosis of MPS, especially in its milder forms and/or initial stages.
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